Louisiana State Employees Retirement System Invests $2.57 Million in IQVIA Holdings Inc. (NYSE:IQV)

Louisiana State Employees Retirement System purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 11,100 shares of the medical research company’s stock, valued at approximately $2,568,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC bought a new position in IQVIA in the 4th quarter worth about $13,759,000. Kentucky Retirement Systems bought a new position in IQVIA in the 3rd quarter worth about $2,994,000. Schwartz Investment Counsel Inc. boosted its stake in IQVIA by 4.1% in the 4th quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock worth $41,345,000 after purchasing an additional 7,050 shares during the period. Dfpg Investments LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at about $1,106,000. Finally, Sei Investments Co. raised its holdings in shares of IQVIA by 20.2% in the 3rd quarter. Sei Investments Co. now owns 94,748 shares of the medical research company’s stock valued at $18,641,000 after acquiring an additional 15,913 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. SVB Leerink initiated coverage on IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective on the stock. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Truist Financial raised their price objective on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. BTIG Research began coverage on IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. Finally, Robert W. Baird raised their price target on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $256.80.

Insider Activity at IQVIA

In related news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock worth $10,331,003 over the last ninety days. 1.60% of the stock is owned by corporate insiders.

IQVIA Price Performance

Shares of IQV stock opened at $231.15 on Tuesday. The firm has a market cap of $41.95 billion, a P/E ratio of 31.71, a P/E/G ratio of 2.27 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The business’s 50 day moving average price is $243.88 and its 200-day moving average price is $221.10. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. During the same period last year, the company earned $2.54 EPS. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.